Endoplasmic reticulum fluorescent probe as well as preparation and application thereof
By designing a fluorescent probe based on the specific affinity of small molecules for ribosomal RNA, the combination of antibiotics and fluorescent dyes is used to solve the problem of insufficient imaging accuracy of the endoplasmic reticulum fluorescent probe, and high-precision endoplasmic Net-targeting and photodynamic therapy reduce the toxicity of the probe and improve the treatment efficiency.
Patent Information
- Application Number
- CN202411005312.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-22
AI Technical Summary
The imaging accuracy of existing endoplasmic reticulum fluorescent probes is insufficient, so they cannot be used for photodynamic therapy, and it is difficult to accurately target the endoplasmic reticulum.
Design a fluorescent probe based on the specific affinity of small molecules for ribosomal RNA, including antibiotics, cell-targeted polypeptide RGD, and fluorescent dyes that can produce singlet oxygen. The antibiotic binds to the ribosome and uses ribosome mediation Targeting the endoplasmic reticulum and producing singlet oxygen under laser irradiation to achieve photodynamic therapy.
High-precision endoplasmic reticulum imaging and treatment are achieved, reducing the physiological and exotoxicity of the probe, and improving the tumor targeting effect and treatment efficiency.
Smart Images

Figure CN118995199A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of fluorescent probes and biomedicine, and more specifically, to a cell endoplasmic reticulum fluorescent probe, preparation and application, and in particular to a cell endoplasmic reticulum fluorescent probe based on the specific affinity of small molecules to ribosomal RNA (rRNA), preparation and application. Background Art
[0002] The endoplasmic reticulum is an important place for lipid synthesis, protein transport and protein folding in cells, and it has close interactions with various organelles in cells. When the endoplasmic reticulum is abnormally damaged, such as the loss of calcium ions, intracellular redox imbalance, and mutant protein expression, misfolded proteins or unfolded proteins will continue to accumulate in the endoplasmic reticulum. After a long period of accumulation, it is not relieved, which in turn causes endoplasmic reticulum damage and inhibits the normal function of the endoplasmic reticulum, which is endoplasmic reticulum stress. Endoplasmic reticulum stress is known to be associated with a variety of diseases, including diabetes, Alzheimer's disease and other diseases. Therefore, further in-depth exploration of the endoplasmic reticulum and precise delivery of drugs that inhibit endoplasmic reticulum stress are of great significance for the treatment of a variety of diseases.
[0003] The endoplasmic reticulum and ribosomes, as the transport center and protein synthesis center of the cell respectively, have a very close synergistic relationship. Especially in tumor cells with uncontrolled proliferation, there is a very high demand for protein synthesis rate, so the abundance of ribosomes can reach 2-3 times that of normal cells, of which more than 85% of ribosomes are dynamically located in the endoplasmic reticulum during translation and complete the translation process in the rough endoplasmic reticulum. Therefore, the interaction between the endoplasmic reticulum and ribosomes can be developed into a new drug delivery mechanism.
[0004] Levofloxacin, as an antibiotic, can specifically bind to bacterial ribosomes and eukaryotic cell ribosomes, but unlike bacteria, it does not cause the death of eukaryotic cells after binding to eukaryotic cell ribosomes. The main reason is that the binding sites of levofloxacin are non-functional sites (sites A, P, and E), so it has the characteristics of low toxicity to eukaryotic cells; and because it has the ability to specifically bind to ribosomal RNA and is further delivered to the endoplasmic reticulum through the ribosome, it can be regarded as a potential endoplasmic reticulum targeting molecule.
[0005] Traditional fluorescent probes targeting the endoplasmic reticulum are designed based on the principle of targeting the endoplasmic reticulum membrane structure with lipophilic molecules. However, due to the influence of multiple membrane structures in the cell, the imaging accuracy is insufficient. Therefore, designing a new endoplasmic reticulum targeting mechanism and developing a highly accurate fluorescent probe is still a huge challenge. Summary of the invention
[0006] In view of the problems existing in the existing endoplasmic reticulum fluorescent probes, the present invention provides a cell endoplasmic reticulum fluorescent probe based on the specific affinity of small molecules for ribosomal RNA (rRNA), comprising sequentially coupled antibiotics, cell targeting polypeptide RGD and fluorescent dyes capable of producing singlet oxygen; the cell targeting polypeptide RGD is used to target cells, the antibiotics are used to anchor ribosomes embedded in the endoplasmic reticulum, and the fluorescent dyes are used for fluorescent imaging and / or producing singlet oxygen. Thus, the technical problems of insufficient imaging accuracy and inability to be used for photodynamic therapy of endoplasmic reticulum fluorescent probes in the prior art are solved.
[0007] According to a first aspect of the present invention, a cell endoplasmic reticulum fluorescent probe is provided, comprising an antibiotic, a cell targeting polypeptide RGD and a fluorescent dye capable of producing singlet oxygen, which are coupled in sequence; the cell targeting polypeptide RGD is used to target cells, the antibiotic is used to anchor ribosomes embedded in the endoplasmic reticulum, and the fluorescent dye is used for fluorescent imaging and / or producing singlet oxygen.
[0008] Preferably, the fluorescent dye capable of generating singlet oxygen is fluorescent dye IR780, fluorescent dye ICG, fluorescent dye Ce6, fluorescent dye Cypate or fluorescent dye Cy5.5.
[0009] Preferably, the antibiotic is levofloxacin, tetracycline or minocycline.
[0010] According to another aspect of the present invention, there is provided a method for preparing any one of the endoplasmic reticulum fluorescent probes, comprising the following steps:
[0011] (1) forming an amide bond between the antibiotic and Boc-ethylenediamine through the mediation of 1-ethyl-(3-dimethylaminopropyl)carbodiimide and 1-hydroxybenzotriazole to obtain a first intermediate;
[0012] (2) removing the protecting group Boc of the first intermediate product obtained in step (1) to obtain a second intermediate product;
[0013] (3) reacting the second intermediate product obtained in step (2) with a bifunctional coupling agent, N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate, to obtain a third intermediate product;
[0014] (4) reacting the third intermediate product obtained in step (3) with the cell targeting polypeptide RGD to obtain a fourth intermediate product;
[0015] (5) The fourth intermediate product obtained in step (4) undergoes a substitution reaction with a fluorescent dye capable of generating singlet oxygen, thereby obtaining the cell endoplasmic reticulum fluorescent probe.
[0016] Preferably, the step (1) uses N,N-diisopropylethylamine as a catalyst.
[0017] Preferably, the step (2) is to remove the protecting group BOC in a mixed solution of trifluoroacetic acid and dichloromethane.
[0018] Preferably, the steps (3), (4) and (5) are all carried out using triethylamine as a catalyst;
[0019] The cell targeting polypeptide RGD in step (4) is a cell targeting cyclic peptide.
[0020] According to another aspect of the present invention, there is provided a use of any one of the endoplasmic reticulum fluorescent probes for preparing a fluorescent imaging agent.
[0021] According to another aspect of the present invention, there is provided a use of any one of the endoplasmic reticulum fluorescent probes for preparing a tumor photodynamic therapy preparation.
[0022] Preferably, the cell endoplasmic reticulum fluorescent probe is used to generate singlet oxygen after laser irradiation, thereby causing damage to the endoplasmic reticulum membrane, inducing endoplasmic reticulum stress and immunogenic death of tumor cells.
[0023] In general, the above technical solution conceived by the present invention has the following technical advantages compared with the prior art:
[0024] (1) The endoplasmic reticulum fluorescent probe in the present invention has high-precision imaging capability and strong specificity: based on the high affinity of antibiotics for eukaryotic cell ribosomes and the basic cellular phenomenon that ribosomes are highly enriched in the endoplasmic reticulum, the ribosomes are used as carriers for intracellular drug transport and the endoplasmic reticulum is precisely targeted.
[0025] (2) The endoplasmic reticulum fluorescent probe in the present invention has a photodynamic therapy effect while imaging, and can achieve integrated treatment and diagnosis. By sequentially coupling antibiotics, cell-targeting peptide RGD and fluorescent dyes that can produce singlet oxygen. While achieving precise targeting of the tumor site of the lesion, the probe enters the cell and binds to the ribosome, thereby reducing the cell's excretion of the probe, achieving accurate and lasting tumor imaging. And after laser irradiation, photodynamic therapy is achieved to kill tumor cells.
[0026] (3) The present invention uses antibiotics to achieve endoplasmic reticulum targeting, which has low toxicity to eukaryotic organisms. By utilizing the differences in the structure and conformation of the ribosomes of eukaryotic cells and prokaryotic cells, while achieving targeting of the ribosomes of eukaryotic cells, it avoids directly binding to the functional sites of the ribosomes, reduces interference with the function of the ribosomes of eukaryotic cells, and effectively reduces the physiological toxicity of the probe. In addition, when the probe is used for photodynamic therapy, precise laser irradiation can be achieved at the lesion site, further reducing the external toxicity of the probe.
[0027] (4) The present invention proposes a new eukaryotic cell endoplasmic reticulum targeting strategy: The antibiotic proposed in the present invention first binds to the ribosome and then uses the ribosome as a carrier to achieve the "organelle hitchhiking" strategy of endoplasmic reticulum targeting. This is the first time that this strategy has been proposed, which can achieve a targeting effect similar to that of existing endoplasmic reticulum dyes. While achieving the endoplasmic reticulum targeting effect, it also minimizes the exogenous toxicity of the probe and improves the potential for in vivo application of the probe. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The present invention provides an organic synthesis process for the fluorescent probe.
[0029] Figure 2 The mass spectra of the intermediate products and the final products in the synthesis process of the fluorescent probe described in the present invention.
[0030] Figure 3 The figure is the ultraviolet absorption spectrum of the fluorescent probe and its synthetic raw materials described in the present invention.
[0031] Figure 4 The figure is a fluorescence spectrum diagram of the fluorescent probe and its synthetic raw materials described in the present invention.
[0032] Figure 5 This is a detection diagram of the ability of the fluorescent probe of the present invention to generate singlet oxygen after being irradiated by laser.
[0033] Figure 6 This is a confocal imaging picture of cells taken up by the fluorescent probe of the present invention after incubation with tumor cells MCF-7.
[0034] Figure 7 The cell survival rates (a) after the fluorescent probe of the present invention was incubated with human breast cancer cells MCF-7, mouse breast cancer cells 4T1 and mouse embryonic fibroblasts 3T3, and the cell survival rates (b) after photodynamic therapy.
[0035] Figure 8 Schematic diagram of the mechanism of the fluorescent probe of the present invention and its targeting to the endoplasmic reticulum in cells.
[0036] Fig. 9 This is a co-localization diagram of the fluorescent probe of the present invention and the endoplasmic reticulum in cells.
[0037] Fig.10 This is a co-localization diagram of the fluorescent probe of the present invention with the cell membrane, mitochondria and lysosome in the cell. DETAILED DESCRIPTION
[0038] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0039] One object of the present invention is to provide a fluorescent probe that can efficiently target the endoplasmic reticulum and explore its synthesis steps. The probe is referred to as L-RI, and its chemical structure is as follows Figure 1 As shown in compound 6:
[0040] The second purpose of the present invention is to utilize the close cooperative relationship between ribosomes and endoplasmic reticulum to realize the drug delivery strategy from ribosomes to endoplasmic reticulum. The front end group antibiotic (such as levofloxacin) of the fluorescent probe is combined with ribosomal RNA, thereby anchoring the fluorescent probe to the ribosome, and then further targeting to the endoplasmic reticulum through the ribosome, thereby realizing endoplasmic reticulum fluorescence imaging.
[0041] The third purpose of the present invention is to utilize the probe's ability to target the endoplasmic reticulum, realize endoplasmic reticulum fluorescence imaging, and deliver a fluorescent dye (such as photosensitizer IR780) that can produce singlet oxygen to the vicinity of the endoplasmic reticulum membrane for photodynamic therapy. For tumor cells, due to their rapid proliferation, they have a higher abundance of ribosomes, which can cause the enrichment of photosensitizers in the endoplasmic reticulum, causing damage to the endoplasmic reticulum membrane after laser irradiation, inducing endoplasmic reticulum stress and cell death, and realizing cell immunogenic death caused by endoplasmic reticulum stress.
[0042] In order to achieve the above object, the technical solution of the present invention is as follows:
[0043] The present invention provides a method for preparing a fluorescent probe for the endoplasmic reticulum of a cell based on the specific affinity of small molecules to ribosomal RNA (rRNA):
[0044] S1: The amide bond between levofloxacin and Boc-ethylenediamine was mediated by 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) and 1-hydroxybenzotriazole (HOBT). Levofloxacin (450 mg, 1.246 mmol, 2 eq), EDC (358 mg, 1.874 mmol, 3 eq), HOBT (253 mg, 1.874 mmol, 3 eq) and Boc-ethylenediamine (100 mg, 0.623 mmol, 1 eq) were co-dissolved in 20 ml of dichloromethane, N,N-diisopropylethylamine (326 ul, 1.874 mmol, 3 eq) was added, and the mixture was stirred at room temperature for 12 h. After repeated vacuum rotary evaporation and concentration, dichloromethane was redissolved, and ultrapure water was extracted three times. The organic phase was collected, concentrated by rotary evaporation, and passed through a normal phase column (dichloromethane: methanol = 100:0-85:15 gradient). After rotary evaporation, a yellow solid was obtained, which was the intermediate product 1 with a molecular weight of 503;
[0045] S2: The protective group BOC in the intermediate product 1 was removed by a mixed solution of trifluoroacetic acid and dichloromethane (trifluoroacetic acid: dichloromethane = 1:5). The intermediate product 1 was dissolved in 20 ml of dichloromethane, trifluoroacetic acid (4 ml) was added, and stirred at room temperature for 8 min. The solution was repeatedly concentrated by vacuum rotary evaporation and redissolved in 10 ml of dichloromethane. The solution was turbid with white precipitate. The precipitate was collected at 7000 rpm / 10 min and washed three times with dichloromethane. It was purified by a normal phase silica gel column with methanol and dichloromethane as the mobile phase to obtain a yellow solid, which was the intermediate product 2 with a molecular weight of 403;
[0046] S3: Intermediate 2 was further reacted with bifunctional coupling agent N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (SMCC). Intermediate 2 (40 mg, 0.1 mmol, 1 eq) and SMCC (82 mg, 0.25 mmol, 2.5 eq) were co-dissolved in 4 ml DMF, triethylamine (40 ul) was added, stirred at room temperature for 6 h, repeatedly concentrated by vacuum rotary evaporation, and purified by normal phase column (dichloromethane: methanol = 95:5-80:20 gradient), with a yield of about 60%, which was intermediate 3, with a molecular weight of 622;
[0047] S4: Intermediate 3 was further reacted with cell-targeted cyclic peptide (RGDCK). Intermediate 3 (28 mg, 0.045 mmol, 2.5 eq) and c(RGDCK) (10 mg, 0.0018 mmol, 1 eq) were co-dissolved in 3 ml DMF, triethylamine (5 ul) was added, and the mixture was stirred at room temperature for 12 h. After repeated vacuum rotary evaporation and concentration, the mixture was washed twice with dichloromethane and twice with ethyl acetate. The precipitate was collected by centrifugation at 7000 rpm / 10 min and dried to obtain a white solid. The reaction product was purified by a reverse phase C18 column with methanol and water as the mobile phase to obtain a white solid, which was intermediate 4 with a molecular weight of 1181.
[0048] S5: Intermediate product 4 undergoes substitution reaction with fluorescent molecule IR780. Intermediate product 4 (20 mg, 0.017 mmol, 1 eq) and IR-780 (28.2 mg, 0.042 mmol, 2.5 eq) were dissolved in 3 ml DMF, triethylamine (10 ul) was added, and the mixture was reacted at 80 °C for 5 h. After repeated vacuum rotary evaporation and concentration, the mixture was washed twice with dichloromethane to obtain a blue precipitate. The mixture was purified by reverse phase C18 column with methanol and water as the mobile phase to obtain a dark blue solid, which was the final product with a molecular weight of 1682.
[0049] The principle of the present invention is as follows: first, antibiotics (such as levofloxacin) and cell-targeted cyclic peptides (RGDCK) are connected by amide bonds, and the cell-targeted cyclic peptides (RGDCK) are coupled with fluorescent dyes (such as photosensitizer IR780) that can generate singlet oxygen through substitution reactions to obtain a three-component small molecule fluorescent probe. Second, antibiotics (such as levofloxacin) have specific binding ability to ribosomal RNA and are low in toxicity to eukaryotic cells. Third, ribosomes have a close interaction with the endoplasmic reticulum, and more than 85% of ribosomes are located in the endoplasmic reticulum.
[0050] Preferably, the fluorescent probe of the present invention has three main components: levofloxacin, cell-targeting cyclic peptide (RGDCK) and photosensitizer IR780.
[0051] Preferably, the fluorescent probe for endoplasmic reticulum targeting in the present invention is an antibiotic (such as levofloxacin).
[0052] Preferably, the cell-targeting and tumor-targeting portion of the fluorescent probe of the present invention is a cell-targeting cyclic peptide (RGDCK).
[0053] Preferably, the molecule used for fluorescence imaging and photodynamic therapy in the fluorescent probe of the present invention is a fluorescent dye that can generate singlet oxygen (such as photosensitizer IR780).
[0054] The fluorescent probe of the present invention can specifically bind to ribosome rRNA and further target to the endoplasmic reticulum mediated by the ribosome.
[0055] The fluorescent probe of the present invention can specifically target the endoplasmic reticulum and serve as an endoplasmic reticulum fluorescent probe to observe the morphology of the endoplasmic reticulum.
[0056] The maximum absorption peak of ultraviolet-visible light of the fluorescent probe of the present invention is located at 820-850nm, and the maximum fluorescence emission peak is located at 850-900nm.
[0057] The fluorescent probe of the invention is used for photodynamic therapy of tumors and induces immunogenic death.
[0058] The fluorescent probe of the present invention can generate singlet oxygen under 660nm or 808nm laser irradiation.
[0059] The following are specific embodiments
[0060] Example 1
[0061] like Figure 1 The embodiment of the present invention provides an organic synthesis process of an endoplasmic reticulum-targeted fluorescent probe. The amide bond between levofloxacin and Boc-ethylenediamine is formed by EDC and HOBT mediation, with N,N-diisopropylethylamine as a catalyst, reacting in dichloromethane at room temperature for 12 hours, purified by a normal phase silica gel column, the mobile phase is methanol and dichloromethane, and a yellow solid is obtained after rotary evaporation, which is intermediate product 1, and its molecular weight is 503; further, the protective group BOC in intermediate product 1 is removed by a mixed solution of trifluoroacetic acid and dichloromethane (trifluoroacetic acid: dichloromethane = 1:5), purified by a normal phase silica gel column, the mobile phase is methanol and dichloromethane, and a yellow solid is obtained, which is intermediate product 2, and its molecular weight is 403; subsequently, intermediate product 2 is further reacted with a bifunctional coupling agent SMCC, with triethylamine as a catalyst, and the reaction product is reacted in N,N-dimethylformamide at room temperature The reaction mixture was stirred for 24 hours and purified by a normal phase silica gel column with methanol and dichloromethane as the mobile phase to obtain an off-white solid, which is the intermediate product 3, and its molecular weight is 622; further, the intermediate product 3 was further reacted with the cell-targeted cyclic peptide c (RGDCK) with triethylamine as the catalyst and reacted in N,N-dimethylformamide at room temperature for 12 hours, and the reaction product was purified by a reverse phase C18 column with methanol and water as the mobile phase to obtain a white solid, which is the intermediate product 4, and its molecular weight is 1181; further, the intermediate product 4 was further substituted with the fluorescent molecule IR780 with triethylamine as the catalyst and reacted in N,N-dimethylformamide at 80 degrees Celsius for 5 hours, and purified by a reverse phase C18 column with methanol and water as the mobile phase to obtain a dark blue solid, which is the final product, and its molecular weight is 1682.
[0062] like Figure 2The embodiment of the present invention provides a mass spectrum of intermediate products and final products in the synthesis process of an endoplasmic reticulum-targeted fluorescent probe. The mass spectrum corresponds to the molecular weight of intermediate 1 of 504.3864 (Z=1), the mass spectrum corresponds to the molecular weight of intermediate 2 of 404.20813 (Z=1), the mass spectrum corresponds to the molecular weight of intermediate 3 of 623.29773 (Z=1) and 312.15259 (Z=2), the mass spectrum corresponds to the molecular weight of intermediate 4 of 1182.55029 (Z=1), 591.77869 (Z=2) and 394.85529 (Z=3), and the mass spectrum corresponds to the molecular weight of the final product of 1684.89332 (Z=1), 842.94971 (Z=2) and 562.63641 (Z=3).
[0063] like Figure 3 The embodiment of the present invention provides an ultraviolet absorption spectrum of the fluorescent probe and its synthetic raw materials. The ultraviolet maximum absorption peak of the fluorescent probe in the ultraviolet absorption spectrum is located at 820-850nm;
[0064] like Figure 4 The embodiment of the present invention provides a fluorescence spectrum of the fluorescent probe and its synthetic raw materials. The maximum fluorescence emission peak of the fluorescence spectrum is located at 850-900nm;
[0065] like Figure 5 The embodiment of the present invention provides a detection diagram of the ability of the fluorescent probe to produce singlet oxygen after being irradiated by laser. After the fluorescent probe and DPBF are co-dissolved, as the 808nm laser irradiation time increases, the ultraviolet absorption value of the singlet oxygen capture agent DPBF at 420nm continues to decrease. It proves that the fluorescent probe can produce singlet oxygen.
[0066] like Figure 6 The embodiment of the present invention provides a confocal imaging image of cells taken up by the fluorescent probe after incubation with tumor cells MCF-7. As the incubation time of the fluorescent probe increases, the fluorescent signal in the cell is significantly enhanced, proving that the fluorescent probe can be taken up by cells.
[0067] like Figure 7 The embodiment of the present invention shown provides the cell survival rate (a) after the fluorescent probe is incubated with human breast cancer cells MCF-7, mouse breast cancer cells 4T1 and mouse embryonic fibroblasts 3T3, and the cell survival rate (b) after photodynamic therapy. When the 808nm laser is not added, the cell survival rate is still above 80% when the fluorescent probe is at 10μM. However, when the 808nm laser is added, the cell survival rate is reduced to below 25% when the fluorescent probe is at 10μM.
[0068] like Figure 8The embodiment of the present invention provides a schematic diagram of the mechanism of the fluorescent probe targeting the endoplasmic reticulum in the cell. The fluorescent probe first binds to the ribosome in the cell, and then targets to the endoplasmic reticulum by utilizing the interaction between the ribosome and the endoplasmic reticulum.
[0069] like Fig. 9 The embodiment of the present invention provides a co-localization diagram of the fluorescent probe and the endoplasmic reticulum in the cell. The co-localization coefficient of the fluorescent probe and the endoplasmic reticulum in the cell can reach 0.9631, proving that the probe can accurately target the endoplasmic reticulum.
[0070] like Fig.10 The embodiment of the present invention provides a co-localization diagram of the fluorescent probe with the cell membrane, mitochondria and lysosome in the cell. The co-localization coefficients of the fluorescent probe with the cell membrane, mitochondria and lysosome in the cell are 0.1145, 0.3914 and 0.2149 respectively, proving that the probe can avoid non-specific binding with other organelles.
[0071] It will be easily understood by those skilled in the art that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A fluorescent probe for endoplasmic reticulum of a cell, characterized in that: The invention comprises an antibiotic, a cell targeting polypeptide RGD and a fluorescent dye capable of generating singlet oxygen, which are coupled in sequence; the cell targeting polypeptide RGD is used for targeting cells, the antibiotic is used for anchoring ribosomes embedded in the endoplasmic reticulum, and the fluorescent dye is used for fluorescent imaging and / or generating singlet oxygen.
2. The cell endoplasmic reticulum fluorescent probe according to claim 1, characterized in that: The fluorescent dye capable of generating singlet oxygen is fluorescent dye IR780, fluorescent dye ICG, fluorescent dye Ce6, fluorescent dye Cypate or fluorescent dye Cy5.
5.
3. The cell endoplasmic reticulum fluorescent probe according to claim 1, characterized in that: The antibiotic is levofloxacin, tetracycline or minocycline.
4. The method for preparing a fluorescent probe of endoplasmic reticulum according to any one of claims 1 to 3, characterized in that: The following steps are involved: (1) forming an amide bond between the antibiotic and Boc-ethylenediamine through the mediation of 1-ethyl-(3-dimethylaminopropyl)carbodiimide and 1-hydroxybenzotriazole to obtain a first intermediate; (2) removing the protecting group Boc of the first intermediate product obtained in step (1) to obtain a second intermediate product; (3) reacting the second intermediate product obtained in step (2) with a bifunctional coupling agent, N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate, to obtain a third intermediate product; (4) reacting the third intermediate product obtained in step (3) with the cell targeting polypeptide RGD to obtain a fourth intermediate product; (5) The fourth intermediate product obtained in step (4) undergoes a substitution reaction with a fluorescent dye capable of generating singlet oxygen, thereby obtaining the cell endoplasmic reticulum fluorescent probe.
5. The method for preparing a fluorescent probe for endoplasmic reticulum of a cell according to claim 4, characterized in that: The step (1) uses N,N-diisopropylethylamine as a catalyst.
6. The method for preparing a fluorescent probe for endoplasmic reticulum of a cell according to claim 4, characterized in that: The step (2) is to remove the protective group BOC in a mixed solution of trifluoroacetic acid and dichloromethane.
7. The method for preparing a fluorescent probe for endoplasmic reticulum of a cell according to claim 4, characterized in that: Step (3), step (4) and step (5) all use triethylamine as a catalyst; The cell targeting polypeptide RGD in step (4) is a cell targeting cyclic peptide.
8. Use of the endoplasmic reticulum fluorescent probe according to any one of claims 1 to 3 for preparing a fluorescent imaging agent.
9. Use of the endoplasmic reticulum fluorescent probe according to any one of claims 1 to 3 for preparing a tumor photodynamic therapy preparation.
10. The use according to claim 9, characterized in that The cell endoplasmic reticulum fluorescent probe is used to generate singlet oxygen after laser irradiation, thereby causing damage to the endoplasmic reticulum membrane, inducing endoplasmic reticulum stress and immunogenic death of tumor cells.
Citation Information
Cited By
Fluorescent nano carbon dot for tumor photodynamic therapy based on ribosome affinity, preparation and application
CN120204415A
